Abstract Library

#4351 Outcomes of lobar and sub-lobar resection for lung neuroendocrine tumours (LNETs, carcinoids) – An ENETS CoE experience

Introduction: LNETs are rare tumours accounting for 1–2% of all lung cancers.

Conference:

Presenting Author:

Authors: Hojerat R, Idaiss I, Aviel G, Korach A, Bel-Ange A,

Keywords: lung neuroendocrine tumour, pulmonary carcinoid, lobar resection, sub-lobar resection, pro-gastrin-releasing peptide,

#3998 Selective internal radiation therapy for neuroendocrine liver metastases: Efficacy, safety and prognostic factors – A retrospective single institution study

Introduction: Selective internal radiation therapy (SIRT) has shown good results in unresectable liver metastases from neuroendocrine neoplasms (NENLMs) with a high disease control rate (DCR) reported (Braat et al., 2019).

Conference:

Presenting Author: Borbath I

Authors: Briol D, Cerrati A, Annet L, Danse E,

Keywords: SIRT, liver metastases, Prognostic factor, safety,

#3852 Novel insights to study the potential of the somatostatin system in NETs and NECs

Introduction: Neuroendocrine tumors (NETs) and carcinomas (NECs) are a heterogeneous group of cancers with increasing incidence worldwide. Surgery is the only curative choice, whereas an effective pharmacological approach for disseminated disease is still lacking. Somatostatin (SS) receptors (SSTs) provide a suitable pharmacological target to treat NETs with SS analogues (SSAs). However, a large proportion of NETs and, particularly most NECs, are unresponsive or resistant to SSAs. The underlying causes remain poorly understood and alternative strategies are needed. Recently, cortistatin (CST), a neuropeptide analogue of SS with comparable affinity to SSTs, emerged as an anti-inflammatory player, with potential antitumoral features.

Conference:

Presenting Author: Mangili F

Authors: Mangili F, Moreno Montilla M, García Vioque V, Blázquez-Encinas R, Mantovani G,

Keywords: PanNET, PanNEC, Somatostatin receptor (SST), cortistatin, Somatostatin,

#3331 Outcomes of upfront treatment with mFOLFIRINOX regimen in G3 GEP-NENs: A monocentric retrospective experience

Introduction: To date outcomes of standard chemotherapy are not homogeneous in different subgroups of G3 GEP-NENs and remain unsatisfactory and poor; new therapeutic options are desirable in this setting.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Borghesani M

Authors: Borghesani M, Reni A, Zaninotto E, Fumagalli A, Benini L,

Keywords: net, mfolfirinox, chemotherapy, g3, minen,

#3328 Role of neoadjuvant PRRT in resectable/borderline resectable PanNETs: Clinical, pathological and genomic features

Introduction: The role of preoperative therapies to obtain cytoreduction, especially PRRT, is unclear.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Fumagalli A

Authors: Fumagalli A, Pellicciari M, Reni A, Borghesani M, Zaninotto E,

Keywords: net, prrt, neuroendocrine tumor, pancreas, genomic, neoadjuvant treatment,